<DOC>
	<DOCNO>NCT02258152</DOCNO>
	<brief_summary>The purpose study placebo-controlled , randomize , double-blind study ass safety efficacy SYN120 patient Parkinson 's disease dementia ( PDD ) already treat stable dose cholinesterase inhibitor .</brief_summary>
	<brief_title>SYN120 Dual 5-HT6/5-HT2A Antagonist Proof Concept Study Evaluate Its Safety , Tolerability Efficacy Parkinson 's Disease Dementia ( SYNAPSE )</brief_title>
	<detailed_description>This study include Screening Period 6 week , 16 week Treatment Period , 2 week Safety Follow Up Period . Final eligibility determine Baseline Visit . Eligible patient randomize receive placebo SYN120 100 mg day ( QD ) .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Serotonin 5-HT2 Receptor Antagonists</mesh_term>
	<criteria>Parkinson 's Disease Dementia Patient routine caregiver Taking stable cholinesterase inhibitor . Patient Montreal Cognitive Assessment ( MoCA ) 1023 inclusive History significant neurologic psychiatric disease PD Any condition clinically significant abnormal finding would make patient unsuitable study Unpredictable motor fluctuation would interfere administer assessment</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>PDD</keyword>
	<keyword>Parkinson 's Disease Dementia</keyword>
	<keyword>patient take cholinesterase inhibitor .</keyword>
</DOC>